PO.MCB07.01 · 分子与细胞生物学

Lurbinectedin改变EWS::FLI1与染色质的结合以毒害转录

Lurbinectedin alters EWS::FLI1 binding to chromatin to poison transcription

海报缩略图:Lurbinectedin改变EWS::FLI1与染色质的结合以毒害转录
编号 4776 展板 26 时间 4/21 09:00–12:00 区域 Section 24 主讲 Zachary Tolstyka, BS;MD;PhD
分会场 Oncogenic Transcription Factors and Cancer Programs
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Zachary P. Tolstyka1, Raphael D. Lopez2, Sridhar M. Veluvolu2, Emma Hiscock1, Andrew Fuller1, Mia Lollo1, Emily Seiden1, Rachael Hinshaw1, Lauren Gaetano2, Elizabeth Wilson2, Gretchen Lam1, Rebecca Kaufman2, Elissa Boguslawski1, Michelle Paulsen1, Ishwarya Narayanan1, Jenna Gedminas2, Mats Ljungman1, Patrick J. Grohar1

1University of Michigan Medical School, Ann Arbor, MI,2Children's Hospital of Philadelphia, Philadelphia, PA

摘要 Abstract

中文摘要
复发性Ewing肉瘤预后极差,在过去30年中治疗进展甚微——迫切需要开发新的治疗方法。该肿瘤在发生和维持恶性状态方面独特地依赖于致癌性EWS::FLI1融合转录因子。Lurbinectedin是天然产物trabectedin的小分子类似物,已在包括Ewing肉瘤在内的多种癌症中显示出疗效。Lurbinectedin对Ewing肉瘤的毒性机制正在研究中。 Lurbinectedin暴露改变了EWS::FLI1向核仁的转运,这一点通过共聚焦显微镜测得。随后,通过CUT&Tag确定了药物暴露对EWS::FLI1与染色质结合的影响,并通过染色质分级分离予以证实。转录通过qPCR和RNAseq评估,并利用BRUseq确定对新生转录的影响。通过邻位连接质谱进一步阐明了机制。最终,将EWS::FLI1的CUT&Tag与Bru-seq相结合(CUT、Tag与Bru)在lurbinectedin处理后阐明了药物对EWS::FLI1结合以及下游转录改变的影响。 将Ewing肉瘤细胞暴露于lurbinectedin改变了EWS::FLI1在细胞核内的分布,使其向核仁转移。通过使用抑制HSP70的增效剂,可将重新定位的EWS::FLI1捕获于核仁中。该重新定位由改变的MAPK信号驱动,可通过siRNA沉默MAPK通路成员而被挽救。该效应源于FET蛋白家族的野生型功能,并与EWS::FLI1在响应元件处结合的改变相关,从而导致转录组的改变。转录起始和延伸均发生改变。重要的是,这些对EWS::FLI1的效应既呈剂量依赖又呈时间依赖,并可通过MAPK扰动剂进一步放大。 用lurbinectedin治疗诱导致癌性转录因子EWS::FLI1重新定位至核仁,导致EWS::FLI1靶基因的转录抑制以及细胞活力的显著下降。这种对EWS::FLI1与染色质结合的调节以浓度依赖和时间依赖的方式发生。有趣的是,这种影响似乎依赖于基因长度:与较短的基因相比,较长的基因发生更大的转录改变。
查看英文原文 English abstract
Relapsed Ewing sarcoma has dismal outcomes and has had minimal treatment advancements in the last 30 years - there is a critical need for the development of new treatments. The tumor is uniquely dependent on the oncogenic EWS::FLI1 fusion transcription factor to develop and maintain malignancy. Lurbinectedin is a small molecule analog of the natural product trabectedin that has shown efficacy in multiple cancers including Ewing sarcoma. The mechanism of toxicity of lurbinectedin in Ewing sarcoma is under investigation. Lurbinectedin exposure alters EWS::FLI1 trafficking into the nucleolus as measured by confocal microscopy. The subsequent impact of drug exposure on EWS::FLI1 binding to chromatin was determined by CUT&Tag and confirmed by chromatin fractionation. Transcription was assessed by qPCR and RNAseq, and BRUseq was utilized to determine the impact on nascent transcription. Further mechanistic clarification was determined by proximity ligation mass spectrometry. Ultimately, the integration of CUT&Tag of EWS::FLI1 with Bru-seq (CUT, Tag, and Bru) following treatment with lurbinectedin elucidated the effects of the drug on EWS::FLI1 binding and alteration of downstream transcription. Exposure of Ewing sarcoma cells to lurbinectedin alters EWS::FLI1 distribution in the nucleus to the nucleolus. The relocalized EWS::FLI1 can be trapped in the nucleolus by use of potentiators that inhibit HSP70. The relocalization is driven by altered MAPK signaling and can be rescued by siRNA silencing of MAPK pathway members. The effect is rooted in wild-type function of the FET family of proteins and is associated with altered EWS::FLI1 binding at response elements leading to alteration of the transcriptome. Both transcription initiation and elongation are altered. Importantly, these effects on EWS::FLI1 are both dose and time dependent and can be further amplified with MAPK perturbants. Treatment with lurbinectedin induces relocalization of the oncogenic transcription factor EWS::FLI1 to the nucleolus leading to transcriptional suppression of EWS::FLI1 target genes and a striking decrease in cell viability. This modulation of EWS::FLI1 binding to chromatin occurs in both a concentration and time dependent manner. Intriguingly, the impact appears to be dependent on gene length: there is greater transcription alteration in longer genes compared to shorter genes.
利益披露 Disclosure
Z. P. Tolstyka, None.. R. D. Lopez, None.. S. M. Veluvolu, None.. E. Hiscock, None.. A. Fuller, None.. M. Lollo, None.. E. Seiden, None.. R. Hinshaw, None.. L. Gaetano, None.. E. Wilson, None.. G. Lam, None.. R. Kaufman, None.. E. Boguslawski, None.. M. Paulsen, None.. I. Narayanan, None.. J. Gedminas, None.. M. Ljungman, None. P. J. Grohar, Orphai Stock Option, ), Other Intellectual Property. PharmaMar Travel, Other, Advisory Board. Jazz Pharmaceuticals Other, Advisory Board.

← 返回 AACR 2026 检索